INCY
INCYTE CORPPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jul 1 HSR Early Termination: Incyte Corporation; Star…
- Jul 31 to Aug 19 ▼ 5 days of insider sells: $6.9M by 2 insiders, avg $121.70
- Aug 10 Trial readout: Results Pending: retifanlimab (Phase 2), Completed 73d ago
- Aug 11 Trial readout: Results Pending: retifanlimab (Phase 2), Completed 74d ago
- Aug 25 Trial readout: Results Pending: retifanlimab (Phase 2), Completed 88d ago
- Sep 4 ▲ Ro Khanna bought $1,001 - $15,000, last disclosed Oct 9
- Sep 15 ▼ 1 insider sell $2.8M at $120.49
- Oct 7 ▼ Ro Khanna sold $1,001 - $15,000, last disclosed Nov 9
- Oct 15 ▼ 1 insider sell $297.8K at $112.71
- Oct 29 ▲ Incyte reported Q3 2026 total revenue of $1.56B (+14% YoY) and total…
- Oct 30 ▲ Oppenheimer upgrades
- Nov 3 to Nov 6 ▼ 2 days of insider sells: $28.5M by 2 insiders, avg $118.39
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $38.5M.
- InstitutionsBULLISH
Q2 2026: 46 added (1 new), 29 trimmed or exited. Largest new: Hrt Financial $17.0M.
- AnalystsBULLISH
19 of 35 rate it Buy or better.
- Short sellersSTEADY
Short interest +6.2% to 10.65M shares. 5.6 days to cover, ≈5.2% of shares.
- TrendUPTREND
1% above its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| HSBC HOLDINGS PLC | DOUBLED | $148.3M |
| PANAGORA ASSET MANAGEMENT INC | TRIM | $100.0M |
| JPMORGAN CHASE & CO | ADD | $87.3M |
| UBS Group AG | TRIM | $87.1M |
| JACOBS LEVY EQUITY MANAGEMENT, INC | TRIM | $83.0M |
| BANK OF AMERICA CORP /DE/ | TRIM | $76.7M |
| LOS ANGELES CAPITAL MANAGEMENT LLC | TRIM | $65.6M |
| SEI INVESTMENTS CO | TRIM | $56.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
35 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 5, 2026 | Leerink Partners MAINTAIN | Outperform |
| Nov 2, 2026 | Bernstein MAINTAIN | Market Perform |
| Oct 30, 2026 | Wells Fargo MAINTAIN | Equal-Weight |
| Oct 30, 2026 | RBC Capital MAINTAIN | Sector Perform |
| Oct 30, 2026 | Barclays MAINTAIN | Overweight |
| Oct 30, 2026 | Evercore ISI Group MAINTAIN | In-Line |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Stein Steven H CMO & Head of Late-Stage Dev. Nov 6, 2026 | EXERCISE | $585.9K |
Stein Steven H CMO & Head of Late-Stage Dev. Nov 6, 2026 | EXERCISE | $1.2M |
Stein Steven H CMO & Head of Late-Stage Dev. Nov 6, 2026 | EXERCISE | $2.2M |
Stein Steven H CMO & Head of Late-Stage Dev. Nov 6, 2026 | EXERCISE | $1.8M |
Stein Steven H CMO & Head of Late-Stage Dev. Nov 6, 2026 | EXERCISE | $99.9K |
Stein Steven H CMO & Head of Late-Stage Dev. Nov 6, 2026 | EXERCISE | $891.5K |
Stein Steven H CMO & Head of Late-Stage Dev. Nov 6, 2026 | EXERCISE | $1.3M |
Stein Steven H CMO & Head of Late-Stage Dev. Nov 6, 2026 | EXERCISE | $1.3M |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
17 filings · 4 bullish · 1 bearish · 1 mixed · 11 neutral- NEUTRAL 144Nov 13, 2026
Heeson Lee, an officer of Incyte, filed a Form 144 notice to sell 10,694 shares of common stock…
This is a routine insider sale tied to RSU vesting, not a discretionary bearish signal. Monitor for any subsequent Form 4 filings to confirm execution, but no further action warranted.
- NEUTRAL 8-KNov 13, 2026
Incyte announced it will not proceed with the planned Phase 3 MAESTRA-3 study of its CDK2…
Monitor Incyte's pipeline updates for reallocation of resources from the cancelled study to other programs. The decision removes a potential catalyst in ovarian cancer but avoids a costly late-stage…
- NEUTRAL SC 13G/ANov 12, 2026
Dodge & Cox filed an amended Schedule 13G disclosing a 5.0% passive stake in Incyte as of…
Monitor whether Dodge & Cox continues to accumulate or stabilizes at this level. As a passive filer, no activist intent is signaled, but the increase following Incyte's Q3 earnings and raised…
- NEUTRAL CLUSTERNov 10, 2026
CMO Steven Stein sold $4.07M in open-market shares under a 10b5-1 plan, and Principal Accounting…
The sales are pre-planned and immaterial in size. No bearish signal; monitor for any unplanned insider selling or changes to 10b5-1 plans.
All INCY filing & press-release reports (17)
- 144 reportNov 13, 2026
- 8-K reportNov 13, 2026
- SC 13G/A reportNov 12, 2026
- CLUSTER reportNov 10, 2026
- 144 reportNov 6, 2026
- 144 reportNov 3, 2026
- 8-K reportOct 29, 2026
- INST-CLUSTER reportOct 23, 2026
- CLUSTER reportAug 14, 2026
- CLUSTER reportAug 7, 2026
- CLUSTER reportAug 4, 2026
- 8-K reportJul 28, 2026
- CLUSTER reportJul 20, 2026
- CLUSTER reportJul 20, 2026
- 8-K reportJun 8, 2026
- DEFA14A reportMay 27, 2026
- INST-CLUSTER reportFeb 28, 2026